Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ebola shield: new trial tests vaccine + antibody cocktail for High-Risk contacts

NCT ID NCT06841614

First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 23 times

Summary

This study tests whether giving a vaccine plus an antibody drug right after high-risk Ebola exposure works better than the vaccine alone. It involves 160 people who have had close contact with an Ebola patient. The goal is to see which approach prevents more people from getting sick.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guinea Centre for Research and Training in Infectious Diseases (CERFIG)

    Conakry, Guinea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Institute for Biomedical Research (INRB)

    Kinshasa, Democratic Republic of the Congo

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Public Health Institute of Liberia

    Monrovia, Liberia

    Contact Email: •••••@•••••

  • University of Sierra Leone College of Medicine and Allied Health Sciences

    Freetown, Sierra Leone

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.